menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ReachMD Faculty

Public Profile

David M. Simpson, MD
David M. Simpson, MD
  • Professor of Neurology
  • Director, Neuromuscular Diseases Division
  • Director, Clinical Neurophysiology Laboratories
  • Icahn School of Medicine, Mount Sinai New York, NY
David M. Simpson, MD, is Professor of Neurology at Icahn School of Medicine at Mount Sinai in New York, New York. He is also Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division. Dr. Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in Neurology at Cornell University Medical Center in New York. He had a fellowship in Clinical Neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts. Dr. Simpson is author of over 248 original peer-reviewed publications, 96 book chapters and, has edited 3 books, and serves on numerous editorial boards. He has been the principal investigator for numerous studies, including the treatment of neuropathic pain in patients with peripheral neuropathy, neurological complications of HIV/AIDS and treatment of spasticity, limb dystonia and tremor with botulinum toxin. He is Chair of the American Academy of Neurology’s Subcommittee charged with generating evidence-based guidelines for the use of botulinum toxin. Dr. Simpson is a member of the American Neurological Association and the American Pain Society, Fellow of the American Academy of Neurology and the American Academy of Neuromuscular and Electrodiagnostic Medicine and President-Elect of the International Neurotoxin Association. He has received the Mitchell B Max Award for Neuropathic Pain from the American Academy of Neurology in 2018, granted for outstanding achievements in the field of neuropathic pain.
Programs 4/21/21